OMAHA, Neb. — Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced today that it has completed a preliminary study with a leading pharmaceutical company that validates the use of its licensed COLD-PCR technology to detect colorectal tumor-associated KRAS mutations that determine efficacy of recently developed therapies. These were detected in plasma samples in which the mutation […]

Patent Licensed From Johns Hopkins University for PCR-based Companion Diagnostics for Cancer Treatments VENLO, The Netherlands — QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. Research has […]

Point-of-care Molecular Diagnostics instruments – Tecan to industrialize and supply commercially manufactured Diagnostics instruments – First demonstration instruments delivered – Commercial launch of Enigma ML for initial use is anticipated in Q4 2010 Männedorf, Switzerland and Oxford, UK — The Tecan Group (SIX Swiss Exchange: TECN), a leading global provider of laboratory instruments and solutions, […]

MANCHESTER, England & NEW YORK–Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial […]

First Commercial Test using SEQureDx Technology for Determining Rhesus D Incompatibility SAN DIEGO — Sequenom, Inc. (Nasdaq: SQNM) today announced the launch of the SensiGene™ Fetal RHD Genotyping test by Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company’s first laboratory developed test powered by its SEQureDx™ […]

Glasgow, Scotland — D3 Technologies Ltd, a world leading provider of trace level detection technologies based on the exploitation of Surface-Enhanced Raman Scattering (SERS) and Surface-Enhanced Resonance Raman Scattering (SERRS), today announced that it has appointed David Burns as its new Chief Executive Officer. He will lead the Company towards the international launch of its […]

SAVANNAH, Ga.–Health Discovery Corporation (OTCBB: HDVY) announced today that the Company has received the final payment that was due under the agreement that settled the Company’s patent infringement lawsuit against Vermillion (Pink Sheets: VRML), formerly known as Ciphergen Biosystems, Inc. In 2006, Health Discovery Corporation sued Ciphergen Biosystems in Federal District Court for infringement of […]

CHICAGO & SANTA CLARA, Calif.–Linden LLC, a Chicago-based healthcare private equity firm, today announced it has acquired Hycor Biomedical Inc. from Agilent Technologies (NYSE:A). Hycor develops, manufactures and markets in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets. Agilent acquired Hycor through its acquisition of Stratagene in 2007. The terms of the […]

REDMOND, Wash.–Micronics, Inc. today announced that it has been issued a second letters patent from the United States Patent and Trademark Office (USPTO) for an integrated heat exchange system on a disposable, plastic cartridge. The new patent has broad utility across the life sciences sector with particular application in point of care molecular diagnostics. “System […]

VANCOUVER, British Columbia–Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has signed a second partner, Guangzhou Wondfo Biotech Co., Ltd. (Wondfo) in China to sell the Company’s diagnostic products, expanding its strategic presence in this important global market. “In 2009, we recognized a significant portion of our revenues from sales in China. […]